中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
22期
38-41
,共4页
徐进%成健康%杜勇%胡素芳
徐進%成健康%杜勇%鬍素芳
서진%성건강%두용%호소방
乳果糖%便秘%肠易激综合征%益生菌
乳果糖%便祕%腸易激綜閤徵%益生菌
유과당%편비%장역격종합정%익생균
Lactulose%Constipation%Irritable bowel syndrome%Probiotics
目的 探讨乳果糖联合枯草杆菌二联活菌治疗便秘型肠易激综合征的临床疗效.方法 选择98例便秘型肠易激综合征患者,根据治疗药物分为3组:乳果糖组33例,枯草杆菌二联活菌组30例,联合治疗组35例,且三组均口服莫沙必利,疗程均为2周,观察患者腹痛、腹胀的症状、大便情况以及治疗前后生活质量改善情况.结果 联合治疗组腹痛和腹胀改善总有效率明显高于乳果糖组和枯草杆菌二联活菌组,乳果糖组明显高于枯草杆菌二联活菌组,差异有统计学意义(P＜0.05).各组间治疗前大便Bristol分级构成比较差异无统计学意义(P＞0.05).各组间治疗后大便Bristol分级构成比较差异有统计学意义(P＜0.05).三组大便Bristol分级构成治疗后与治疗前比较差异有统计学意义(P＜ 0.05).治疗前三组间生活质量评分比较差异无统计学意义(P＞0.05),三组治疗后生活质量评分均高于治疗前,差异有统计学意义(P＜0.05);治疗后联合治疗组生活质量评分明显高于乳果糖组,乳果糖组明显高于枯草杆菌二联活菌组,差异有统计学意义(P＜0.05).结论 乳果糖联合枯草杆菌二联活菌治疗便秘型肠易激综合征明显优于单用乳果糖及枯草杆菌二联活菌,值得临床应用.
目的 探討乳果糖聯閤枯草桿菌二聯活菌治療便祕型腸易激綜閤徵的臨床療效.方法 選擇98例便祕型腸易激綜閤徵患者,根據治療藥物分為3組:乳果糖組33例,枯草桿菌二聯活菌組30例,聯閤治療組35例,且三組均口服莫沙必利,療程均為2週,觀察患者腹痛、腹脹的癥狀、大便情況以及治療前後生活質量改善情況.結果 聯閤治療組腹痛和腹脹改善總有效率明顯高于乳果糖組和枯草桿菌二聯活菌組,乳果糖組明顯高于枯草桿菌二聯活菌組,差異有統計學意義(P＜0.05).各組間治療前大便Bristol分級構成比較差異無統計學意義(P＞0.05).各組間治療後大便Bristol分級構成比較差異有統計學意義(P＜0.05).三組大便Bristol分級構成治療後與治療前比較差異有統計學意義(P＜ 0.05).治療前三組間生活質量評分比較差異無統計學意義(P＞0.05),三組治療後生活質量評分均高于治療前,差異有統計學意義(P＜0.05);治療後聯閤治療組生活質量評分明顯高于乳果糖組,乳果糖組明顯高于枯草桿菌二聯活菌組,差異有統計學意義(P＜0.05).結論 乳果糖聯閤枯草桿菌二聯活菌治療便祕型腸易激綜閤徵明顯優于單用乳果糖及枯草桿菌二聯活菌,值得臨床應用.
목적 탐토유과당연합고초간균이련활균치료편비형장역격종합정적림상료효.방법 선택98례편비형장역격종합정환자,근거치료약물분위3조:유과당조33례,고초간균이련활균조30례,연합치료조35례,차삼조균구복막사필리,료정균위2주,관찰환자복통、복창적증상、대편정황이급치료전후생활질량개선정황.결과 연합치료조복통화복창개선총유효솔명현고우유과당조화고초간균이련활균조,유과당조명현고우고초간균이련활균조,차이유통계학의의(P＜0.05).각조간치료전대편Bristol분급구성비교차이무통계학의의(P＞0.05).각조간치료후대편Bristol분급구성비교차이유통계학의의(P＜0.05).삼조대편Bristol분급구성치료후여치료전비교차이유통계학의의(P＜ 0.05).치료전삼조간생활질량평분비교차이무통계학의의(P＞0.05),삼조치료후생활질량평분균고우치료전,차이유통계학의의(P＜0.05);치료후연합치료조생활질량평분명현고우유과당조,유과당조명현고우고초간균이련활균조,차이유통계학의의(P＜0.05).결론 유과당연합고초간균이련활균치료편비형장역격종합정명현우우단용유과당급고초간균이련활균,치득림상응용.
Objective To investigate the therapeutic efficacy of lactulose combined with Bacillus subtilis duplex living bacterium in patients with constipation-predominant irritable bowel syndrome.Methods A total of 98 patients with constipation-predominant irritable bowel syndrome were divided into 3 groups according to the therapeutic drugs:lactulose group (33 cases),Bacillus subtilis duplex living bacterium group (30 cases) and combined treatment group (35 cases),and patients in all groups received mosapride.The course of treatment was 2 weeks in all groups.The symptoms of patients with abdominal pain,abdominal distention,defecate condition and quality of life before and after treatment was observed.Results The total efficacy of abdominal pain,abdominal distention in combined treatment group was higher than that in lactulose group and Bacillus subtilis duplex living bacterium group,in lactulose group was higher than that in Bacillus subtilis duplex living bacterium group,and there was significant difference (P ＜ 0.05).There was no significant difference in defecate Bristol grade before treatment among three groups (P ＞ 0.05).There was significant difference in defecate Bristol grade after treatment among three groups(P ＜ 0.05).There was significant difference in defecate Bristol grade before and after treatment in three groups(P ＜ 0.05).There was no significant difference in the quality of life before treatment among three groups (P ＞ 0.05),the quality of life after treatment in three groups was higher than that before treatment,and there was significantdifference (P ＜ 0.05).After treatment,the quality of life in combined treatment group was higher than that in lactulose group,in lactulose group was higher than that in Bacillus subtilis duplex living bacterium group,and there was significant difference (P ＜ 0.05).Conclusions The combined regimen of lactulose and Bacillus subtilis duplex living bacterium is more effective than lactulose or Bacillus subtilis duplex living bacterium alone.Thus the combined regimen of lactulose and Bacillus subtilis duplex living bacterium is an effective therapeutic method for constipation-predominant irritable bowel syndrome.
